(Q37641326)

21 August 2017

1 reference

title

Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog (English)

1 reference

21 August 2017

1 reference

1 reference

1 reference

Jerry Meece

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

29

1 reference

21 August 2017

issue

12 Pt 2

1 reference

21 August 2017

page(s)

33S-42S

1 reference

Five stages of evolving beta-cell dysfunction during progression to diabetes

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

beta-cell failure in diabetes and preservation by clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

The glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Potential of liraglutide in the treatment of patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Diseases of liporegulation: new perspective on obesity and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Regulation of beta-cell mass by hormones and growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Diabetes and protein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Comment on: Lachin et al. (2007) The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the diabetes control and complications trial: Diabetes 56:1913-1921, 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro by dog plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

The physiology and pharmacology of incretins in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.33S

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.PT2.33S

1 reference

21 August 2017

1 reference